Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Modified Osteoporosis Drugs Kill Malaria Parasite in Mice

By BiotechDaily International staff writers
Posted on 20 Mar 2012
Chemical modification of the bone-resorption bisphosphonate drugs zoledronate and risedronate enables effective targeting of the elusive intraerythrocytic form of the malaria parasite Plasmodium falciparum.

The modification enables the drugs to cross the cell membrane and thereby readily enter the infected red blood cells (RBCs). Here they act as potent inhibitors of a key enzyme, geranylgeranyl diphosphate synthase (GGPPS), in isoprenoid biosynthesis, an essential survival and defense pathway for the parasite. The drugs have little effect on this pathway in human or mouse cells.

Scientists identified the modified drugs with an in vitro assay targeting the RBC form of P. falciparum in screening a library of several hundred drug compounds known to be isoprenoid biosynthesis inhibitors. Based on "growth-rescue" and enzyme-inhibition experiments, GGPPS was shown to be a major target for the most potent leads, labeled BPH-703 and BPH-811, lipophilic analogs of zoledronate and risedronate.

“We found that compounds that were really active had a very long hydrocarbon chain. These compounds can cross the cell membrane and work at very low concentrations,” said Eric Oldfield, PhD and professor of chemistry at the University of Illinois at Urbana-Champaign (UIUC; IL, USA). Compared to the parent compounds, the lipophilic analogs show enhanced binding to the target GGPPS enzyme and only the lipophilic species are active in cells.

In vivo, the drugs were effective against Plasmodium with no observed toxicity to the mice – BPH-703 and BPH-811 tested in mice both resulted in major decreases in parasitemia and 100% mouse survival.

“It’s important to find new drug targets because malaria drugs last only a few years, maybe 10 years, before you start to get resistance,” Oldfield said. Study coauthor Yonghui Zhang, research scientist in Prof. Oldfield’s lab, noted, “We are the first to show that the enzyme GGPPS is a valid target for malaria."

The study appears in the March 5, 2012, edition of the journal Proceedings of the National Academy of Sciences USA. These results are also of broader interest as they indicate that it may be possible to overcome barriers to cell penetration of existing bisphosphonate drugs in this and other systems by simple covalent modification to form lipophilic analogs that retain their enzyme-inhibition activity and are also effective in vitro and in vivo.

Related Links:
University of Illinois at Urbana-Champaign




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.